Table of Contents
ISRN Vascular Medicine
Volume 2011 (2011), Article ID 141430, 9 pages
http://dx.doi.org/10.5402/2011/141430
Review Article

Glycoprotein IIb/IIIa Antagonists in Acute Coronary Syndromes Undergoing PCI: A Long Way to Select Optimal Agent and Route

1Laboratrio di Biotechnologie Applicate alla Medicina Cardiovascolare, Dipartimento di Fisiopatologia Cardiocircolatoria, Anestesiologia e Chirurgia, Istituto del Cuore “Attilio Reale”, Sapienza Università di Roma, Rome 00161, Italy
2Section of Cardiology, Department of Internal Medicine, University of Bologna, 40126 Bologna, Italy

Received 24 March 2011; Accepted 9 May 2011

Academic Editors: J. L. Fleg and A. Hirata

Copyright © 2011 Paolo Emilio Puddu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Valgimigli and M. Minarelli, “Antiplatelet and antithrombotic treatment after primary percutaneous coronary intervention: balancing safety and efficacy,” American Heart Journal, vol. 160, no. 6, pp. S36–S41, 2010. View at Publisher · View at Google Scholar · View at PubMed
  2. G. De Luca, E. P. Navarese, E. Cassetti, M. Verdoia, and H. Suryapranata, “Meta-analysis of randomized trials of glycoprotein IIb/IIIa inhibitors in high-risk acute coronary syndromes patients undergoing invasive strategy,” American Journal of Cardiology, vol. 107, no. 2, pp. 198–203, 2011. View at Publisher · View at Google Scholar · View at PubMed
  3. G. De Luca, E. Navarese, and P. Marino, “Risk profile and benefits from Gp IIb/IIIainhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials,” European Heart Journal, vol. 30, no. 22, pp. 2705–2713, 2009. View at Publisher · View at Google Scholar · View at PubMed
  4. F. Ottani, L. La Vecchia, M. De Vita, O. Catapano, F. Tarantino, and M. Galvani, “Comparison by meta-analysis of eptifibatide and tirofiban to abciximab in patients with st-elevation myocardial infarction treated with primary percutaneous coronary intervention,” American Journal of Cardiology, vol. 106, no. 2, pp. 167–174, 2010. View at Publisher · View at Google Scholar · View at PubMed
  5. V. L. Serebruany, S. R. Steinhubl, P. B. Berger, A. I. Malinin, D. L. Bhatt, and E. J. Topol, “Variability in platelet responsiveness to clopidogrel among 544 individuals,” Journal of the American College of Cardiology, vol. 45, no. 2, pp. 246–251, 2005. View at Publisher · View at Google Scholar · View at PubMed
  6. S. R. Steinhubl, P. B. Berger, J. T. Mann III et al., “Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial,” JAMA, vol. 288, no. 19, pp. 2411–2420, 2002. View at Publisher · View at Google Scholar
  7. G. Montalescot, G. Sideris, C. Meuleman et al., “A randomized comparison of high clopidogrel loading doses in patients with non–ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial,” Journal of the American College of Cardiology, vol. 48, no. 5, pp. 931–938, 2006. View at Publisher · View at Google Scholar · View at PubMed
  8. N. von Beckerath, A. Kastrati, A. Wieczorek et al., “A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days,” European Heart Journal, vol. 28, no. 15, pp. 1814–1819, 2007. View at Publisher · View at Google Scholar · View at PubMed
  9. D. J. Angiolillo, S. B. Shoemaker, B. Desai et al., “Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the optimizing antiplatelet therapy in diabetes mellitus (OPTIMUS) study,” Circulation, vol. 115, no. 6, pp. 708–716, 2007. View at Publisher · View at Google Scholar · View at PubMed
  10. S. F. Mehta, F. Van de Werf et al., “A randomized comparison of a clopidogrel high loading and maintenance dose regimen versus standard dose and high versus low dose aspirin in 25,000 patients with acute coronary syndromes: results of the CURRENT OASIS 7 Trial,” Tech. Rep., European Society of Cardiology, Barcelona, 2009, http://www.escardio.org/congresses/esc-2009/congress-reports/Pages/706003-706004-mehta-vandewerf.aspx#discussant. View at Google Scholar
  11. R. S. Hermanides, J. P. Ottervanger, and J. P. Dambrink, “Risk of bleeding after prehospital administration of high dose tirofiban for ST elevation myocardial infarction,” International Journal of Cardiology. In press.
  12. M. Lotrionte, G. G. L. Biondi-Zoccai, P. Agostoni et al., “Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention,” American Journal of Cardiology, vol. 100, no. 8, pp. 1199–1206, 2007. View at Publisher · View at Google Scholar · View at PubMed
  13. S. D. Wiviott, D. Trenk, A. L. Frelinger et al., “Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial,” Circulation, vol. 116, no. 25, pp. 2923–2932, 2007. View at Publisher · View at Google Scholar · View at PubMed
  14. G. Dangas, R. Mehran, G. Guagliumi et al., “Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial,” Journal of the American College of Cardiology, vol. 54, no. 15, pp. 1438–1446, 2009. View at Publisher · View at Google Scholar · View at PubMed
  15. J. R. Timmer, J. Ten Berg, A. A. Heestermans et al., “Pre-hospital administration of tirofiban in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: a sub-analysis of the On-Time 2 trial,” EuroIntervention, vol. 6, pp. 336–342, 2010. View at Google Scholar
  16. G. P. Talarico, M. Brancati, F. Burzotta et al., “Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the “OPTIMIZE-IT” pilot randomized study,” Journal of Cardiovascular Medicine, vol. 10, no. 3, pp. 245–251, 2009. View at Publisher · View at Google Scholar · View at PubMed
  17. R. Waksman, “IIb or Not IIb: is there a place for pre-hospital tirofiban in ST-segment elevation myocardial infarction patients?” Journal of the American College of Cardiology, vol. 55, no. 22, pp. 2456–2458, 2010. View at Publisher · View at Google Scholar · View at PubMed
  18. S. C. Smith Jr., T. E. Feldman, J. W. Hirshfeld Jr. et al., “ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart association Task Force on Practice Guidelines (ACC/AHA/SCAI writing Committee to update the 2001 Guidelines for percutaneous coronary intervention),” Journal of the American College of Cardiology, vol. 47, no. 1, pp. e1–e121, 2006. View at Publisher · View at Google Scholar · View at PubMed
  19. L. Dong, F. Zhang, and X. Shu, “Early administration of small-molecule glycoprotein IIb/IIIa inhibitors before primary percutaneous coronary intervention for st-elevation myocardial infarction: insights from randomized clinical trials,” Journal of Cardiovascular Pharmacology and Therapeutics, vol. 15, no. 2, pp. 135–144, 2010. View at Publisher · View at Google Scholar · View at PubMed
  20. M. Valgimigli, G. Biondi-Zoccai, M. Tebaldi et al., “Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials,” European Heart Journal, vol. 31, no. 1, pp. 35–49, 2010. View at Publisher · View at Google Scholar · View at PubMed
  21. U. Zeymer, A. Margenet, M. Haude et al., “Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI trial,” Journal of the American College of Cardiology, vol. 56, no. 6, pp. 463–469, 2010. View at Publisher · View at Google Scholar · View at PubMed
  22. A. Akerblom, S. K. James, M. Koutouzis et al., “Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry),” Journal of the American College of Cardiology, vol. 56, no. 6, pp. 470–475, 2010. View at Publisher · View at Google Scholar · View at PubMed
  23. M. Schiariti, A. Saladini, B. Missiroli et al., “Safety of downstream high-dose tirofiban bolus among 1578 patients undergoing percutaneous coronary intervention: the Sant'ANna TIrofiban safety study,” Journal of Cardiovascular Medicine, vol. 11, no. 4, pp. 250–259, 2010. View at Publisher · View at Google Scholar · View at PubMed
  24. M. Schiariti, A. Saladini, F. Papalia et al., “GPIIb/IIIa receptor antagonism using small molecules provides no additive long-term protection after percutaneous coronary intervention as compared to clopidogrel plus aspirin,” Open Cardiovascular Medicine Journal, vol. 4, pp. 151–156, 2010. View at Publisher · View at Google Scholar · View at PubMed
  25. L. De Luca, G. Casella, M. Lettino et al., “Clinical implications and management of bleeding events in patients with acute coronary syndromes,” Journal of Cardiovascular Medicine, vol. 10, no. 9, pp. 677–686, 2009. View at Publisher · View at Google Scholar · View at PubMed
  26. P. B. Berger, “The glycoprotein IIb/IIIa inhibitor wars,” Journal of the American College of Cardiology, vol. 56, no. 6, pp. 476–478, 2010. View at Publisher · View at Google Scholar · View at PubMed
  27. D. J. Schneider and A. Aggarwal, “Development of glycoprotein IIb/IIIaantagonists: translation from pharmacodynamic effect to clinical benefit,” Expert Review of Cardiovascular Therapy, vol. 2, no. 6, pp. 903–913, 2004. View at Publisher · View at Google Scholar · View at PubMed
  28. E. J. Topol, D. J. Moliterno, H. C. Herrmann et al., “Comparison of two glycoproteins IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization,” The New England Journal of Medicine, vol. 344, no. 25, pp. 1888–1894, 2001. View at Publisher · View at Google Scholar · View at PubMed
  29. C. Le Pen and H. Lilliu, “GPIIb/IIIa antagonist in percutaneous coronary intervention: how should economic criteria be factored in?” Pharmacy World and Science, vol. 27, no. 2, pp. 83–91, 2005. View at Publisher · View at Google Scholar
  30. S. J. Brener, “The benefits of platelet glycoprotein IIb/IIIa receptor inhibition during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: drug-specific or class effect?” Journal of the American College of Cardiology, vol. 53, no. 18, pp. 1674–1676, 2009. View at Publisher · View at Google Scholar · View at PubMed
  31. F. Zijlstra, “The benefits and risks of Abciximab, eptifibatide, or tirofiban during PCI: class effects or do they differ?” Catheterization and Cardiovascular Interventions, vol. 73, no. 2, pp. 222–223, 2009. View at Publisher · View at Google Scholar · View at PubMed
  32. M. Schiariti, A. Saladini, D. Cuturello, B. Missiroli, and P. E. Puddu, “Long-term efficacy of high-dose tirofiban versus double-bolus eptifibatide in patients undergoing percutaneous coronary intervention,” Journal of Cardiovascular Medicine, vol. 12, pp. 29–36, 2011. View at Publisher · View at Google Scholar · View at PubMed
  33. F. G. Kushner, M. Hand, S. C. Smith Jr et al., “Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,” Journal of the American College of Cardiology, vol. 54, pp. 2205–2241, 2009. View at Google Scholar
  34. G. G. Biondi-Zoccai, M. Valgimigli, I. Sheiban et al., “A randomized trial comparing eptifibatide versus placebo in patients with diffuse coronary artery disease undergoing drug-eluting stent implantation: design of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial,” Journal of Cardiovascular Medicine, vol. 9, no. 9, pp. 957–962, 2008. View at Publisher · View at Google Scholar · View at PubMed
  35. C. D'Andrea, G. Esposito, F. Piscione, and M. Chiariello, “Tirofiban administration and percutaneous coronary intervention with stenting of saphenous vein graft thrombosis,” Journal of Cardiovascular Medicine, vol. 10, no. 11, pp. 875–878, 2009. View at Publisher · View at Google Scholar · View at PubMed
  36. G. Sardella, G. M. Sangiorgi, M. Mancone et al., “A multi center randomized study to evaluate intracoronary abciximab with the ClearWay catheter to improve outcomes with Lysis (IC ClearLy): trial study design and rationale,” Journal of Cardiovascular Medicine, vol. 11, pp. 529–535, 2010. View at Google Scholar